Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 8-K (Current Report)
Date of Report: July 14, 2025
Event: BD announced definitive agreements to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction. The BD business will be spun off into a wholly-owned subsidiary ("SpinCo") and then merged with Waters.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain periodic financial statements (e.g., revenue, profit, cash flow, or margins) for a specific reporting period. The filing lists the following securities registered on the New York Stock Exchange:
- Common stock (BDX)
- 1.900% Notes due December 15, 2026 (BDX26)
- 1.208% Notes due June 4, 2026 (BDX/26A)
- 1.213% Notes due February 12, 2036 (BDX/36)
- 0.034% Notes due August 13, 2025 (BDX25A)
- 3.519% Notes due February 8, 2031 (BDX31)
- 3.828% Notes due June 7, 2032 (BDX32A)
Note: Specific values for debt, liquidity, or operating metrics are not provided in this text.
Material Changes
The primary material change is the structural separation of BD's Biosciences and Diagnostic Solutions business. This transaction represents a significant strategic shift, effectively divesting these segments to combine them with Waters Corporation. No other operational or financial changes for the current period are detailed in this filing.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- BD and Waters expect to realize synergies from the transaction, though specific amounts and timing are not quantified in this filing.
- A joint conference call and webcast were held on July 14, 2025, to discuss the transaction.
- Investors are directed to future filings (Form S-4 and Form 10) for detailed financial projections and transaction terms.
- Regulatory Approval: The transaction is subject to regulatory approvals, which may be delayed, denied, or conditioned.
- Stockholder Approval: The transaction requires approval from Waters' stockholders.
- Integration Risks: Failure to realize anticipated benefits, delays in integration, or difficulties in achieving revenue and cost synergies.
- Operational Disruption: Risks related to management distraction, retention of key personnel, and separation of the SpinCo business from BD's remaining operations.
- Legal and Tax: Potential stockholder litigation, changes in tax regimes, or failure to obtain anticipated tax treatment.
- Market Conditions: Volatility from tariffs, economic conditions, or industry-specific changes.
Investor Verification Checklist
- Verify the final terms of the Reverse Morris Trust transaction in the upcoming Form S-4 and Form 10 filings.
- Confirm the timeline for regulatory approvals and stockholder votes.
- Review the detailed financial projections and synergy estimates in the attached investor presentations (Exhibits 99.2 and 99.3).
- Assess the impact of the spin-off on BD's remaining business segments and debt structure.
- Monitor for any litigation or regulatory challenges that could delay or terminate the deal.